Object. The authors present the long-term follow-up results (minimum 5 years) of patients with essential trigeminal neuralgia (TN) who were treated with gamma knife surgery (GKS).
GKS and they have attempted to find an optimal balance between good pain relief and minimal side effects. The results are encouraging but many of these studies involve a short follow-up time. 3, 11, 13 In the current study we present results at 5-year follow up.
Clinical Material and Methods

Patient Population
Between 1995 and 2004, 290 patients suffering from essential TN underwent GKS. The median follow up in the current series is 5 years (range 12-96 months). Some patients have been lost to follow up; however, there are 107 patients who fulfill the necessary criteria and who have been followed. The median age was 75 years and the age range was 45 to 91 years ( Table 1 ). The female/male ratio was 61:46.
All patients underwent a complete neurological examination before the treatment. Follow-up neurological assessments and examinations were performed at 1 month, 6 months, and every 1 to 2 years thereafter. In addition to the neurological status, tactile and pain sensations were evaluated.
Nineteen of those patients underwent repeated GKS for recurrent pain after a median latency of 12.5 months (range 3-60 months). The median follow up after the second GKS was 36 months (range 12-72 months).
Radiosurgery Technique
The Leksell gamma knife model B (Elekta Instruments AB, Stockholm) was used for the treatment. Target localization was achieved using magnetic resonance imaging and was performed on a Siemens Magnetom Expert 1T Treatment of essential trigeminal neuralgia with gamma knife surgery with a three-dimensional FLASH, T 1 -weighted sequence and 1.3-mm slice thickness. Treatment planning was performed with Leksell GammaPlan (Elekta). The trigeminal nerve root was chosen as the target for irradiation and the isocenter was placed so that 20% isodose tangentially touched the surface of adjacent brainstem. A 4-mm collimator and a single shot with a maximum dose of 70 Gy (36 cases) or 80 Gy (71 cases) was used. The maximum dose to the brainstem ranged from 10 to 20 Gy (median and mean 14 Gy) and depended on the angle between the root of the trigeminal nerve and the surface of brainstem and thus on the position of shot; the lesser the angle, the higher the dose to the brainstem.
The repeated irradiation was focused 2 to 4 mm distal to the previous target, and the same maximal dose was applied.
Clinical Characteristics
All patients originally suffered from the typical idiopathic TN with a spontaneous onset of episodic facial pain. The pain distribution in the different branches of the trigeminal nerve is shown in Table 1 . The V 2 branch was the most frequently involved (88.8%). The majority of patients (64 or 60%) had undergone some type of prior neurosurgical intervention including radiofrequency rhizotomy, glycerol rhizotomy, balloon microcompression, microvascular decompression, and peripheral neurectomy. The median number of prior surgical procedures was two (range one-eight). Forty-three patients (40%) underwent GKS as the first treatment. Preoperative findings before GKS included facial hypesthesia in 24 cases (22.4%).
Pain Relief
The patients classified their degree of pain relief by using a percentile scale with 0% being pain free and 100% being no change. The patients were divided into five groups according to their perception of residual pain as follows: Group I, excellent (0%); Group II, very good (1-25%), Group III, good (26-50%); Group IV, poor (51-75%); and Group V, very poor (76-100%). Pain relief that could be categorized as Group I, II, and III was considered to be a successful treatment.
Statistical Analysis
Statistical evaluation was performed with commercially available statistical software (SPSS version 10.0). To study distribution of selected events in time, the Kaplan-Meier statistical model was used. The following events were studied: pain relief, occurrence of hypesthesia, pain recurrence after the first treatment, pain recurrence after the second treatment, and occurrence of hypesthesia after the second GKS. The log-rank test was used to determine whether there was a significant difference in pain relief for different numbers of operations before GKS and whether hypesthesia prior the GKS had a significant influence on the increase of hypesthesia after the GKS. The Fisher exact test was used to identify whether pain relief was associated with hypesthesia after GKS. The marginal homogeneity test was used to study whether there was a significant relationship between hypesthesia in a given branch of the nerve after the GKS and pain in this branch before the treatment.
Results
After Initial GKS
Pain Relief. Eighty-six patients (80.4%) were pain free (Group I), 11 patients (10.3%) classified their pain as Group II, six patients (5.6%) as Group III, and four (3.7%) as Group V. No patients rated their pain as Group IV. The GKS was initially successful, according to our definition, in 96% of the patients and failed in 4% as shown in Table 2 . The median interval between GKS and complete pain relief was 3 months (range 1 day-13 months), as shown in Fig. 1 .
In Group I there were 33 patients (38.4%) who underwent GKS as the primary procedure and 53 patients (61.6%) who had undergone other prior interventions. Moreover, the presence or absence of prior interventions had no influence on the results of GKS according to our statistical analysis. We did find, however, a significant link between Group I and new or worse sensory impairment after GKS (Fisher exact test, p = 0.021).
Recurrence of Pain. Recurrence of pain is illustrated in Table 2 Trigeminal neuralgia results after GKS median interval of 36 months (range 6-94 months).
Recurrence was defined as deterioration in a patient who had self-rated their pain as Grades I to Grade IV or V or if the patient moved from Group III to Group V. Side Effects. After GKS there was new hypesthesia or deterioration of existing hypesthesia in 21 patients (20%). Facial sensory loss is recorded in Table 2 and Fig. 3 . The median time to facial sensory impairment was 35 months (range 3-94 months). In all these patients but one the region of hypoesthesia after GKS involved at least in part the region of trigeminal branches where pretreatment pain had been localized. Moreover, in 48% of these cases the hypesthesia appeared in the area in which previous neuralgia only had been present. These links were statistically significant (p = 0.0317, p = 0.0194, respectively). We did not find a significant relationship between the pretreatment sensory impairment and the appearance of new or worsening hypesthesia after GKS Outcome of Pain Relief. Eleven patients (58%) rated their pain as Group I, four patients (21%) as Group II, two patients (10.5%) as Group III (good), one patient (5.3%) as Group IV, and in one patient (5.3%) the GKS completely failed. The treatment was successful in 89% of patients (Groups I, II, and III). The median time to pain relief was 1 month (range 1 week-12 months) after the second irradiation as recorded in Table 3 .
Recurrence of Pain. Pain recurred in only one patient 21 months after the second GKS.
Side Effects. The results for sensory impairment are shown in Table 3 and Fig. 4 . Side effects appeared in six patients (32%) after a median latency of 21 months (range 1-72 months).
Discussion
Gamma knife surgery for TN has come to be seen as a rewarding treatment method. The initial overall success rate was 96% in our patients and 80% of them were pain free after GKS. Moreover, the results reported by different authors are fairly similar, and the success rate is generally excellent or very good. The differences recorded are in part details of treatment technique, such as the maximum dose and the target localization. Brisman 1 (maximum dose 76.8 Gy) reported initial successful pain relief in 80% of patients, and Pollock, et al., 13 (maximum dose 70 and 90 Gy) in 86% and 93% of patients, respectively. Massager, et al., 10 (maximum dose 90 Gy) were successful in treating 94% of D. Urgosik, et al. patients and Kondziolka, et al., 7 (maximum dose from 60-90 Gy) in treating 85.6%.
In practice the only significant side effect after GKS is sensory impairment. Gamma knife surgery is considered to be a safe method with a low rate of complications. In this study facial hypesthesia after GKS occurred in 20% of patients. This rate is higher than has been previously reported. Brisman 1 described sensory impairment in 3.2% of cases, and Massager, et al., 10 had 4% of patients with bothersome facial numbness. Kondziolka, et al., 7 reported facial paresthesias or numbness in 10%. Han, et al., 3 noted 7% of patients with new facial numbness. Our own preliminary results 16 published in 1998 documented only 6% of patients with hypesthesia, similar to the findings reported in the multicenter study. 8 Originally we thought that the higher incidence of postirradiation hypesthesia was a consequence of the increased occurrence of a pretreatment sensory deficit produced by prior surgical procedures. The connection between prior hypesthesia and worsening of existing or evocation of the new sensory impairment has not been statistically validated in this study. It seems more likely the higher incidence is associated with the length of follow up in this study. This is in keeping with the observation that the median latency to this complication is 35 months (range 1-94 months). Because the maximum follow up is 96 months the number of patients with a delayed sensory disturbance is necessarily going to be higher in studies with shorter follow up. In other studies the maximum follow up was 53 months in Brisman 1 , 42 months in Massager, et al., 10 and 9 months in Han, et al. 3 Our previous study 16 comprised a maximum follow up of 19 months. Only Kondziolka, et al., 7 had a similar duration of follow up to that in the current study, with a maximum of 80 months. Another reason for the lower incidence of sensory disturbance in some other reports may be that data were collected by mail and phone call. 10, 15 These data collection methods could result in the patients only mentioning symptoms that were severe, and slight or mild hypesthesia may not have been disclosed. In the current series all patients were examined personally by the treatment staff.
The recurrence of pain in some patients in this study was very late, up to 96 months after GKS. Shetter, et al., 15 and
Herman, et al., 5 found a relationship between postirradiation facial hypesthesia and pain relief. Our results are similar. These findings support the idea that slight damage to the trigeminal nerve is necessary to achieve pain relief after GKS. Also, experimental data 6 support this opinion. The pain relief usually appeared prior to sensory impairment. Complete pain relief occurred after a median latency of 3 months, and sensory impairment occurred after a median latency of 35 months. In addition pain recurrence appeared after a median interval of 36 months, approximately at the same time when sensory disturbances occurred. It is of interest that we found a statistically significant relation between the pretreatment distribution of pain in the trigeminal area and the localization of hypesthesia, when it occurred, after GKS. This finding suggests that nerve fibers of the trigeminal branch involved in neuralgic pain have a decreased resistance and are generally more sensitive to external force than others. The initial success rate after the second irradiation was 88% and in 12% of cases GKS failed. Thirty-three percent of patients reported new or increased facial impairment. To date, pain relapse has occurred in only one patient 21 months after the second GKS. Brisman 2 used a maximum dose of 40 Gy at the second GKS and achieved successful pain relief in 62% of cases and in 4% of patients new significant dysesthesia developed. Shetter, et al., stated an overall success rate in 85% and in 42% of patients there was new-onset facial numbness. They applied 35 to 80 Gy to the 100% dose point. Hasegawa, et al., 4 delivered 64 Gy in the second GKS. The target was placed anterior to the first target so that two radiosurgical volumes overlapped by 50%. They achieved a success rate of 85% and a new sensory symptoms rate of 11% occurred. Although there is variation in these results it seems nevertheless clear that a second GKS can be successful with an acceptable risk of side effects.
Conclusions
Gamma knife surgery is a safe, effective treatment. Side effects seem to be limited to sensory impairment that is usually mild in intensity. This study emphasizes the importance of longer follow-up studies. Repeated GKS was well tolerated with satisfactory pain relief.
